S-1/A: ZyVersa Therapeutics Faces Nasdaq Delisting, Seeks Capital Amid Going Concern Doubts

Sentiment:

Registration Statement Amendment 1 August 2025 5:27 PM

📋All filings for Zyversa Therapeutics, INC

ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, is raising up to $14.1 million through equity agreements and warrant exercises while navigating a Nasdaq delisting and significant going concern doubts.

Capital raiseEntered into an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC to sell up to $10 million of common stock.Received approximately $2.05 million in gross proceeds from the exercise of Series A-2 and A-3 Warrants.Issued Series A-4 Warrants exercisable for 6,124,930 shares, which could generate approximately $4.1 million if fully exercised for cash.The company explicitly states it will need to raise substantial additional capital to develop and commercialize its product candidates.Future financing methods may include public or private equity offerings, debt financings, or corporate collaborations and licensing arrangements.

Worse than expectedThe company's common stock was delisted from The Nasdaq Capital Market due to non-compliance with minimum bid price requirements.The independent registered public accounting firm's report for the year ended December 31, 2024, contains an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.Current cash on hand is "vastly inadequate" and only sufficient for month-to-month operations, indicating severe liquidity issues.The company has not generated any revenue since inception and has incurred substantial net losses.The potential for significant dilution (up to 23,624,938 shares) from the current offering and future capital raises is substantial.The stock now trades on the less regulated Pink Limited Market, which is associated with lower liquidity and higher volatility.

Summary

ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, is registering up to 23,624,938 shares of common stock for resale by selling stockholders.
The company entered into an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC on June 24, 2025, allowing it to sell up to $10 million in common stock through June 24, 2027.
On July 9, 2025, the company completed an inducement transaction, receiving approximately $2.05 million in gross proceeds from the exercise of Series A-2 and A-3 Warrants at a reduced price of $0.67 per share, and issued Series A-4 Warrants exercisable for 6,124,930 shares.
Trading of the company's common stock on The Nasdaq Capital Market was suspended on July 17, 2025, due to non-compliance with minimum bid price requirements, and it now trades on the OTCQB Venture Market under the symbol ZVSA.
The company's independent registered public accounting firm's report for the year ended December 31, 2024, includes an explanatory paragraph expressing substantial doubt about its ability to continue as a going concern.
The company's cash on hand is considered "vastly inadequate" and sufficient only for month-to-month anticipated cash requirements.
The company will not receive proceeds from the resale of shares by selling stockholders but may receive up to $10 million from the Williamsburg agreement and approximately $4.1 million from Series A-4 warrant exercises.
The company's pipeline includes VAR 200 for renal diseases (Phase 2a for FSGS, initiated Phase 2a for diabetic kidney disease) and IC 100 for inflammatory conditions (preclinical, planned IND submission H2-2025).

Sentiment

Score: 2

Explanation: The filing reveals severe financial distress, including a Nasdaq delisting, an auditor's going concern doubt, and critically low cash reserves. While new capital arrangements are in place, they come with significant dilution and do not fully resolve the underlying financial instability. The company's clinical pipeline progress is overshadowed by its precarious financial position.

Positives

Secured potential access to up to $10 million in capital through an equity line of credit with Williamsburg Venture Holdings, LLC.
Successfully raised approximately $2.05 million in gross proceeds from the exercise of Series A-2 and A-3 Warrants.
Advanced VAR 200 into Phase 2a clinical trials for diabetic kidney disease, aiming for quicker proof-of-concept data.
IC 100, a humanized monoclonal antibody for inflammatory conditions, is nearing completion of preclinical development with a planned IND submission in H2-2025.
The company has two proprietary, globally licensed drug development platforms with potential for indication expansion.

Negatives

Trading of common stock on The Nasdaq Capital Market was suspended on July 17, 2025, due to non-compliance with minimum bid price requirements.
The company's independent registered public accounting firm expressed substantial doubt about its ability to continue as a going concern in its report for the year ended December 31, 2024.
Current cash on hand is "vastly inadequate" and only sufficient to meet anticipated cash requirements on a month-to-month basis.
The company has not generated any revenue from operations since inception and has incurred substantial net losses.
Significant dilution is expected for existing stockholders due to the potential issuance and resale of up to 23,624,938 shares.
The common stock now trades on the less regulated Pink Limited Market, which may lead to unfavorable stock price impact, lower liquidity, and increased volatility.
There is no assurance that the Series A-4 Warrants will be exercised, as their exercise price may be higher than the prevailing market price, potentially limiting expected proceeds.

Risks

Investors may lose all of their investment due to the high degree of risk associated with the securities.
The actual number of shares sold under the Purchase Agreement or issued upon exercise of Series A-4 Warrants, and the resulting gross proceeds, are uncertain and may be less than anticipated.
The exercise price of the Series A-4 Warrants may be higher than the prevailing market price, leading to non-exercise and no proceeds from them.
Limitations in the Purchase Agreement, such as the 19.99% beneficial ownership limit, may restrict the company's ability to fully utilize the equity line of credit.
Investors purchasing shares at different times will likely pay different prices and experience varying levels of dilution.
The issuance and sale of shares to selling stockholders may cause substantial dilution to existing stockholders and could cause the stock price to decline.
Trading on the Pink Limited Market may result in an unfavorable impact on stock price and liquidity, subject to abuses, volatility, and shorting.
The company may be unable to continue as a going concern, potentially leading to liquidation of assets at significantly lower values.
The company will need substantial additional capital for product development and commercialization, which may not be available on acceptable terms or at all.
Future equity offerings could significantly dilute existing stockholders, and debt financing may impose restrictive covenants.
Collaborations and licensing arrangements may require relinquishing rights to technologies or product candidates on unfavorable terms.
The company's ability to maintain adequate technology, intellectual property, data privacy, and cybersecurity practices.
Reliance on third parties for operations.
Risks related to general economic and financial market conditions, including supply chain disruptions and inflationary cost pressures.
The possibility of an economic recession.
Impact of the political, legal, and regulatory environment.
The changing landscape of the industries in which the company operates.
The outbreak of infectious diseases (e.g., COVID-19) or other epidemics/pandemics disrupting business plans, product development, and clinical trials.
Geopolitical changes and changes in applicable laws or regulations.
Operational risks.
Litigation and regulatory enforcement risks, including diversion of management time and attention and additional costs.

Future Outlook

The company expects its research and development expenses to increase as it progresses clinical trials for VAR 200 and continues preclinical development of IC 100. It plans an IND submission for IC 100 in H2-2025, followed by a Phase 1 trial. The company will need substantial additional capital to develop and commercialize its product candidates and expects to finance future cash needs through public or private equity offerings, debt financings, or corporate collaborations and licensing arrangements. It is currently seeking to uplist to the OTCQB Venture Market, though there is no assurance of success.

Industry Context

ZyVersa Therapeutics operates in the highly capital-intensive biopharmaceutical industry, where clinical-stage companies typically incur substantial losses and require significant ongoing funding for research, development, and regulatory approvals. The company's recent Nasdaq delisting and reliance on over-the-counter markets highlight the challenges faced by smaller biotechs in maintaining exchange listings, especially when facing financial distress and low stock prices. The pursuit of an equity line of credit and warrant exercises is a common strategy for such companies to secure capital, albeit often at the cost of significant shareholder dilution, which is a prevalent concern in this sector.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Bylaw Amendment Requirement	Stockholders require an affirmative vote of at least sixty-six and two-thirds percent (66 2/3%) of the voting power of all outstanding voting stock to adopt, amend, or repeal the Bylaws.	NA	Increases difficulty for stockholders to unilaterally change bylaws, reinforcing board control.
Director Removal Standard	Directors may be removed only for cause and only by the affirmative vote of the holders of at least a majority of the voting power of all outstanding voting stock.	NA	Makes it more difficult for stockholders to remove directors, enhancing board stability but potentially reducing accountability.
Board Vacancy Filling	Vacancies on the board of directors and newly created directorships are filled exclusively by the affirmative vote of a majority of the directors then in office, not by stockholders.	NA	Concentrates power to fill board seats within the existing board, limiting stockholder influence over board composition.
Staggered Board Terms	The board of directors is divided into three classes with staggered three-year terms.	NA	Makes it more difficult for a third party to gain control of the board quickly, serving as an anti-takeover measure.
Special Meeting Call Restrictions	Special meetings of stockholders can only be called by the Chairperson of the board, the board of directors, or the Chief Executive Officer or President, and can be postponed, rescheduled, or canceled by the board or person calling the meeting.	NA	Limits stockholders' ability to call special meetings to address urgent matters or propose changes.
Prohibition of Written Consent	Any action required or permitted to be taken by stockholders must be effected at an annual or special meeting, and may not be taken by written consent in lieu of a meeting.	NA	Prevents stockholders from taking action without a formal meeting, potentially delaying urgent decisions or changes.
Advance Notice Requirements	Bylaws establish advance notice procedures for stockholder proposals and director nominations, requiring timely written notice in proper form.	NA	May preclude stockholders from bringing matters before meetings without sufficient prior planning and adherence to strict rules.
Forum Selection Clause	Designates the Delaware Court of Chancery as the exclusive forum for certain internal corporate claims and federal district courts of the United States as the exclusive forum for Securities Act claims.	NA	Centralizes litigation in specific jurisdictions, potentially increasing convenience for the company but limiting options for plaintiffs.
Director/Officer Indemnification	Provides for indemnification of current and former directors and officers to the fullest extent permitted by Delaware law, including advancement of expenses.	NA	Protects directors and officers from personal liability and costs, potentially reducing their accountability for certain actions.

Stakeholder Impact

Shareholders: Face significant dilution from the issuance of new shares, potential decline in stock price due to delisting and trading on a less regulated market, and substantial risk of losing their investment due to the company's going concern doubts and inadequate cash position.
Employees: The company's precarious financial position and going concern doubts could impact job security and future compensation.
Creditors: The "going concern" doubt and inadequate cash position increase the risk for creditors, potentially affecting the company's ability to meet its obligations.
Customers/Patients (future): Delays or curtailment of product development programs due to insufficient capital could impact the availability of future treatments for chronic renal or inflammatory diseases.
Suppliers: Financial instability could affect the company's ability to pay suppliers in a timely manner.

Next Steps

Initiate a larger Phase 2a/b protocol in patients with FSGS after obtaining proof-of-concept data from the diabetic kidney disease trial for VAR 200.
Advance IC 100 toward a planned Investigational New Drug (IND) submission in H2-2025.
Initiate a Phase 1 trial for IC 100 in healthy overweight patients with a BMI between 27-30.
Initiate an IND-enabling preclinical study for IC 100 in an animal model of diet-induced obesity.
Seek to uplist to the OTCQB Venture Market.
Potentially file additional registration statements for resale of shares if the full $10 million investment amount is to be realized from Williamsburg.
Obtain stockholder approval for the issuance of Warrant Shares under applicable Nasdaq rules.

Key Dates

Date	Description
2014	Year of ZyVersa Therapeutics, Inc. 2014 Equity Incentive Plan.
December 15, 2015	VAR 200 licensed from L&F Research LLC.
April 18, 2019	IC 100 licensed from InflamaCore, LLC.
January 9, 2020	First Amendment to License Agreement between L&F Research LLC and Variant Pharmaceuticals, Inc.
January 21, 2020	Investigational New Drug (IND) application filed for VAR 200.
July 20, 2022	Date of Business Combination Agreement between Old ZyVersa, Larkspur Health Acquisition Corp., and Larkspur Merger Sub, Inc.
December 12, 2022	Closing Date of the business combination; Larkspur changed name to ZyVersa Therapeutics, Inc.; Merger Sub merged into Old ZyVersa.
December 23, 2021	Date of Larkspur's initial public offering (IPO).
January 13, 2023	Issued 29 shares of common stock to a consultant for services.
January 13, 2023	Issued 343 shares of common stock to a consultant for services.
May 19, 2023	Issued 1,086 shares of common stock to a consultant for services.
June 5, 2023	Issued 8,703 shares of common stock to investors for increasing lockup duration.
July 7, 2023	Date of Amendment No. 2 to Form S-1 Registration Statement.
July 26, 2023	Completed a public offering and filed Post-Effective Amendment No. 1 to Form S-1 Registration Statement.
September 14, 2023	Issued 20,347 shares of common stock underlying warrants in an inducement transaction.
October 20, 2023	Registration statement on Form S-1 (File No. 333-268934) declared effective by SEC.
November 30, 2023	Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation filed with Delaware Secretary of State.
December 6, 2023	Date of Securities Purchase Agreement and Placement Agency Agreement.
December 11, 2023	Completed a public offering and filed Current Report on Form 8-K.
December 14, 2023	Issued 9,000 shares of common stock to a consultant for services.
December 22, 2023	Letter from Ernst & Young LLP to SEC.
January 2, 2024	Issued 9,000 shares of common stock to a consultant for services.
April 25, 2024	Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation filed with Delaware Secretary of State.
August 1, 2024	Date of Inducement Letter and Financial Advisory Agreement.
October 7, 2024	Issued 21,000 shares of common stock to a consultant for services.
October 14, 2024	Issued 30,000 shares of common stock to a consultant for services.
November 5, 2024	Date of Inducement Letter.
November 6, 2024	Date of Financial Advisory Agreement.
December 31, 2024	Fiscal year end for which independent registered public accounting firm's report expressed doubt about going concern.
January 17, 2025	Definitive Proxy Statement on Schedule 14A filed with SEC.
February 3, 2025	Issued 60,000 shares of common stock to a consultant for services.
March 5, 2025	Date of Securities Purchase Agreement and Placement Agency Agreement.
March 7, 2025	Issued and sold pre-funded warrants and Series A-3 common stock purchase warrants in a private placement.
March 27, 2025	Date of Marcum LLP's report on financial statements for year ended December 31, 2024.
April 7, 2025	Letter from Marcum LLP to SEC.
April 9, 2025	Registration statement filed on Form-3 (File No. 333-286396) declared effective by SEC.
April 11, 2025	Issued 100,000 shares of common stock to a consultant for services.
April 17, 2025	Definitive Proxy Statement on Schedule 14A filed with SEC.
May 12, 2025	Quarterly Report on Form 10-Q for quarter ended March 31, 2025, filed.
May 13, 2025	Issued 100,000 shares of common stock to a consultant for services.
May 30, 2025	Current Report on Form 8-K filed with SEC.
June 12, 2025	Current Report on Form 8-K filed with SEC.
June 24, 2025	Entered into Equity Purchase Agreement and Registration Rights Agreement with Williamsburg Venture Holdings, LLC.
June 25, 2025	Current Report on Form 8-K filed with SEC.
June 30, 2025	Number of shares of Common Stock outstanding (7,935,921) used as basis for post-offering calculation.
July 8, 2025	Entered into Inducement Letter with a Selling Stockholder.
July 9, 2025	Consummated transactions under Inducement Letter, received gross proceeds of approximately $2.05 million, and issued Series A-4 Warrants.
July 11, 2025	Date for which selling stockholder holdings and outstanding capital stock are reported.
July 15, 2025	Received determination letter from Nasdaq denying request to continue listing.
July 16, 2025	Current Report on Form 8-K filed with SEC.
July 17, 2025	Trading in Common Stock on Nasdaq suspended at market open; expected to begin trading on Pink Limited Market.
July 30, 2025	Last reported sale price for Common Stock on OTCQB was $0.20 per share.
August 1, 2025	As filed date of the S-1/A Amendment No. 2; date of prospectus.
June 24, 2027	Earlier of the two dates for the term of the Purchase Agreement with Williamsburg.

Recommendation

strong sell

The filing presents a highly concerning financial picture for ZyVersa Therapeutics. The Nasdaq delisting, coupled with the auditor's explicit 'going concern' doubt and the company's admission of 'vastly inadequate' cash reserves, signals severe financial distress. While the company is attempting to raise capital through equity lines and warrant exercises, these efforts are highly dilutive and may not be sufficient to address the fundamental liquidity issues or ensure long-term viability. The move to the less regulated Pink Limited Market further exacerbates liquidity and price volatility risks. Given the significant financial instability, high risk of capital loss, and lack of clear path to sustainable operations, a strong sell recommendation is warranted for investors to mitigate further losses.

Keywords

Biopharmaceutical, Clinical Stage, SEC Filing, S-1/A, Equity Offering, Warrants, Dilution, Nasdaq Delisting, Going Concern, Capital Raise, VAR 200, IC 100, Renal Disease, Inflammatory Disease, FSGS, Diabetic Kidney Disease, Obesity, Cardiometabolic, OTC Markets, Pink Limited Market, Williamsburg Venture Holdings, Armistice Capital

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.